ArticleInternational journal of obesity (2005)2026
The impact of slope-adjusted visit-to-visit body mass index variability on early dementia risk prediction.
Article in International journal of obesity (2005), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies have not typically separated body mass index (BMI) slope and variability as distinct constructs when examining dementia risk. This study assessed the association between the slope-adjusted visit-to-visit BMI variability and dementia risk. SUBJECTS/
methodsWe conducted a retrospective cohort study using Japanese national health insurance data (2015-2023) of individuals aged 50-74 years who underwent five annual health checkups. BMI variability was assessed using the slope-adjusted standard deviation (SD) to account for underlying temporal trends. The proxy outcome for dementia was antidementia drug initiation, analyzed using Fine-Gray competing risk models, accounting for death as a competing risk.
resultsDuring the mean 2.17 ± 1.19 years of follow-up among 303,042 participants (mean age: 66.6 years, men: 38.6%), antidementia drugs (predominantly donepezil: 67.4%) were initiated in 665 and 2394 died. After adjusting for covariates including BMI at baseline and annual BMI change, the highest tertile of slope-adjusted BMI-SD (≥0.50 kg/m²) was significantly associated with increased dementia risk compared with the lowest tertile (≤0.31 kg/m²). Annual BMI change showed a U-shaped association with dementia risk, with pronounced elevation in the first tertile (BMI decline ≤-0.31%, hazard ratio: 1.60, 95% confidence interval: 1.32-1.93). In the basic model including baseline covariates except BMI at baseline, there was no significant difference in the C-statistics improvements when BMI at baseline or adding slope-adjusted BMI-SD (+0.0147 vs +0.0146) were added, while the greatest C-statistics improvement was observed when BMI decline ≤-0.31% was added. The association between the highest slope-adjusted BMI-SD tertile and dementia risk was stronger in females than males (P for interaction = 0.0039).
conclusionsSlope-adjusted visit-to-visit BMI variability is independently associated with dementia risk, particularly among females, while BMI decline patterns are strong risk factors of dementia. Incorporating longitudinal monitoring of visit-to-visit BMI variability into routine dementia screening may be beneficial.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.